ivim Health Reviews 2026: Verdict

ivim's pricing structure includes a separate membership fee that is not always clear in marketing materials.

The membership fee includes unlimited provider visits, health coaching, nutritional counseling, 24/7 clinical support, and mobile app access. First month membership may be waived on some plans.

Long-term plan pricing (medication only, membership separate):

HSA and FSA payments are accepted. Klarna financing is available for patients who prefer installment plans.

Comparison with no-membership platforms:

ivim offers the lowest total semaglutide cost among major platforms. The trade-off is the mandatory membership and fixed-term commitments with no mid-term cancellation.

For standard dosing information, see our semaglutide dosage chart, tirzepatide dosage chart, and compound tirzepatide dosage chart.

ivim follows a four-step process from sign-up to ongoing treatment. The entire onboarding takes under 10 minutes, but medication delivery requires 10 to 14 days.

Step 1: Free online consultation. Patients complete a health questionnaire covering medical history, current medications, and weight loss goals. No video call is required for the initial intake.

Step 2: Provider review and prescription. A licensed provider reviews the questionnaire and determines eligibility. Payment is collected at this stage, before clinical approval is finalized. This is a major complaint driver in negative reviews.

Step 3: Medication shipped from partner compounding pharmacy. If approved, the prescription is sent to a licensed compounding pharmacy. Standard shipping takes 10 to 14 days via UPS or FedEx.

Step 4: Weekly check-ins and dose adjustments. Patients use the ivim app for weekly check-ins. Providers adjust dosing based on real-time patient data through ivim's GLP-1 ID protocol. This protocol removes the fixed titration schedule used in standard clinical practice. Instead, doses are individualized based on tolerance, side effects, and progress.

ivim is available in 49 states plus Washington, D.C. Mississippi is the only excluded state.

On February 20, 2026, the FDA issued a warning letter to IVIM Services LLC citing violations of the Federal Food, Drug, and Cosmetic Act, per the FDA warning letter dated February 20, 2026.

What the FDA found. ivim's website displayed compounded semaglutide and tirzepatide products with "Ivim" on the label. This created the false impression that ivim compounds the medications itself. In reality, ivim is a telehealth platform that partners with external compounding pharmacies.

Specific violations cited:

• Section 502(a): Misbranded drugs (misleading labeling)
• Section 502(bb): Failure to meet compounding requirements
• Section 301(a): Introduction of misbranded drugs into interstate commerce

What this means for patients. The FDA gave ivim 15 business days to respond or face potential seizure of products and injunction. The warning letter does not mean the medications are unsafe. It means the marketing and labeling misrepresent who manufactures them.

Broader context. The FDA has been aggressively enforcing compounded GLP-1 regulations since declaring the semaglutide and tirzepatide shortages resolved. Multiple compounding pharmacies and telehealth platforms have received warning letters or faced enforcement actions.

ivim has publicly advocated for continued patient access to compounded GLP-1s. The company frames the crackdown as a patient access issue. For the broader regulatory landscape, see our FDA peptide crackdown analysis and our guide on whether compound tirzepatide is safe.

ivim has the largest review volume among telehealth GLP-1 platforms. This provides a more representative picture than competitors with fewer reviews.

Trustpilot: 4.0/5 (35,742 reviews), according to Trustpilot (March 2026).

The distribution shows a polarized pattern common in telehealth. The majority of reviews are positive (4-5 stars), but a significant minority (estimated 15-20%) are strongly negative (1 star).

What users praise: - Competitive pricing (cheapest compounded semaglutide among major platforms) - Provider quality and availability - Easy onboarding (under 10 minutes) - Real weight loss results (patients report 15 to 40+ pounds) - Comprehensive support model (coaching, nutrition, clinical access)

What users complain about: - Billing before clinical approval (payment collected before prescription is confirmed) - No mid-term cancellation on prepaid plans - Shipping delays (10 to 14 days standard, worse during demand spikes) - Medication batching (paid for 6 months, received in 1 to 2 month shipments) - Formulation changes without disclosure - Buggy mobile app (crashes, incorrect dose tracking, sync failures)

BBB: A+ rating (accredited since February 2023, 77 complaints in 3 years). This is the strongest BBB profile among the telehealth GLP-1 platforms we have reviewed. Zealthy has no rating, MEDVi had an F rating, and Ellie MD has an A without accreditation.

ivim published two peer-reviewed studies in the journal Obesity Pillars, featured in Medscape in March 2026. No major competitor has published comparable clinical data for their patient population.

Study details. The primary study tracked 1,131 patients over 68 weeks. Participants achieved 21.8% average total body weight loss. For comparison, Novo Nordisk's STEP 1 randomized controlled trial reported 14.9% weight loss with branded semaglutide.

ivim's marketing describes this as a "46% improvement" over STEP 1 results. This comparison requires important context.

Critical caveats to consider:

• Study design: ivim's study was observational, not a randomized controlled trial. STEP 1 was an RCT with a placebo control group. These are fundamentally different study designs that cannot be directly compared.
• No control group: Without a placebo arm, the ivim study cannot isolate the effect of medication from lifestyle changes, coaching, or other variables.
• Company-sponsored: The research was funded and conducted by ivim, introducing potential bias.
• Selection bias: Patients who stay in a program for 68 weeks are likely more motivated and adherent than average. Dropouts are not accounted for in the headline figure.
• The "46% improvement" claim is ivim marketing, not a conclusion validated by independent peer review or regulatory bodies.

The studies suggest ivim's integrated approach (medication plus coaching plus individualized dosing) may produce strong outcomes. However, the observational design and company sponsorship mean these results should be interpreted cautiously, not as proof of superiority over standard GLP-1 prescribing.

Source: ivimhealth.com/ivim-glp1-prescribing-study/, Obesity Pillars journal.

ivim's pricing advantage is real. At approximately $150 per month total for compounded semaglutide, it undercuts every competitor by $30 to $150 per month. The question is whether the FDA warning letter and operational complaints offset the savings.

For patients who prioritize cost above all else, ivim delivers the lowest price. For patients who prioritize trust signals, MEDVi (4.4/5 Trustpilot, no FDA issues) or Hims (established brand) are safer choices.

For a detailed look at the Willow platform, see our Willow weight loss reviews.

ivim is a reasonable fit if you:

• Prioritize the lowest possible monthly cost for compounded GLP-1 medication
• Want a comprehensive program (unlimited visits, coaching, nutrition counseling)
• Are comfortable with the FDA warning letter context (labeling issue, not medication safety)
• Can accept 10 to 14 day shipping times and potential delays
• Are willing to commit to a fixed-term plan

ivim is not recommended if you:

• Need flexible month-to-month billing with easy cancellation
• Cannot tolerate shipping delays (medication interruptions affect treatment)
• Want the clearest possible regulatory standing
• Prefer brand-name medications over compounded (ivim offers both, but compounded is the value proposition)
• Need your medication within days, not weeks